DrugPatentWatch Database Preview
ARANESP Drug Profile
Summary for Tradename: ARANESP
| Patents: | 83 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for ARANESP |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARANESP |
Recent Clinical Trials for ARANESP
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Leiden University Medical Center | Phase 2/Phase 3 |
| The Hospital for Sick Children | Phase 2 |
| Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research | Phase 2/Phase 3 |
Recent Litigation for ARANESP
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Ameranth, Inc. v. Starbucks Corporation | 2013-05-06 |
Pharmacology for ARANESP
| Ingredient-type | Erythropoietin |
| Physiological Effect | Increased Erythroid Cell Production |
Company Disclosures: US Patents for ARANESP
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2003-12-13 | RX | company | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2024-05-15 | RX | company | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 002 | 2001-09-17 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2003-12-13 | RX | company | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 002 | 2001-09-17 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2024-05-15 | RX | company | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 003 | 2001-09-17 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2003-12-13 | RX | company | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 003 | 2001-09-17 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2024-05-15 | RX | company | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 004 | 2001-09-17 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2003-12-13 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for ARANESP
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | AMGEN INC. (Thousand Oaks, CA) | 2039-02-26 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | 2036-04-01 | RX | search | ||
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | YALE UNIVERSITY (New Haven, CT) | 2039-02-26 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | GENOSCIENCE PHARMA (Marseilles, FR) | 2039-02-26 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | ChemoCentryx, Inc. (Mountain View, CA) | 2036-06-13 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA) | 2034-08-08 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for ARANESP
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5844971 | Start Trial |
| Costa Rica | 10838 | Start Trial |
| European Patent Office | 2464369 | Start Trial |
| Norway | 20092203 | Start Trial |
| Canada | 2614687 | Start Trial |
| Israel | 96581 | Start Trial |
| European Patent Office | 2295427 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ARANESP
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| PA2004015 | Lithuania | Start Trial | PRODUCT NAME: DARBEPOETINAS ALFA (ASN30 THR32 VAL87 ASN88 THR90 EPO); REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608 |
| 43/2001 | Austria | Start Trial | PRODUCT NAME: DARBEPOETIN-ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608 |
| SPC/GB01/055 | United Kingdom | Start Trial | PRODUCT NAME: DARBEPOETIN ALFA; REGISTERED: UK EU/1/01/185/001-030 20010608 |
| 01C0050 | France | Start Trial | PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608 |
| 10199059 | Germany | Start Trial | PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608 |
| 300075 | Netherlands | Start Trial | PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608 |
| SZ 43/2001 | Austria | Start Trial | PRODUCT NAME: DARBEPOETIN-ALFA |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
